WG102

WG102 is an investigational stem cell-based therapy developed by Shenzhen Wingor Biotechnology. It is part of a specialized pipeline of cellular medicines (WG101–WG108) designed to address a broad range of conditions, including immune-mediated, chronic, and degenerative diseases, as well as rare diseases and tumors. As of the current development cycle, WG102 has progressed to the clinical application stage, with its Investigational New Drug (IND) application accepted by the National Medical Products Administration (NMPA) and the Center for Drug Evaluation (CDE) in China. While the specific stem cell source and exact molecular targets remain proprietary, the therapy is intended to leverage the regenerative and immunomodulatory properties of stem cells to restore physiological function in targeted tissues.